Myostatin levels are elevated in sarcopenic and nonsarcopenic patients with COPD when compared to control groups, which are correlated to a reduced muscle mass [11,225,227,228,229]. The gene discussed is MSTN; the disease is chronic obstructive pulmonary disease.